Gilead’s HIV pill could be market leader in 3-5 years: J.P. Morgan

(Reuters) – J.P. Morgan Securities raised its price target on Gilead Sciences Inc to $ 75 from $ 70, saying the company’s HIV pill could emerge as a “market leader” in three to five years, sending the drugmaker’s shares to a life-high. U.S. health regulators approved the four-drug combination pill, Stribild, on August 27. Physicians said there were no major concerns with Stribild or with its cost, the brokerage said after a survey of 52 HIV specialists. Analyst Geoff Meacham, who reiterated his “overweight” rating on the stock, expects Stribild sales of about $ 2. …
Sexual Health News Headlines – Yahoo! News